46LOW

PAB

PATRYS FPO [PAB]
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.
· ASX Small Cap
$0.0290 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical48
Catalyst53
Sentiment50
Fundamental29
Momentum54
Risk Gate37
Get alerts when PAB's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track PAB — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Drifting lower — down 9.4% over the last 5 days
  • Lagging the Small Ords index — relative strength of 0.79, underperforming its peers
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Low cash runway (3 quarters) - dilution risk
  • Very high P/S ratio (98.4x)
  • Revenue in sharp decline (-100%)
  • Near 52-week low (17% of range)
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (3.11%/day)
  • Altman Z-Score distress zone (1.24 < 1.81, low-confidence approx)
  • Low-priced stock risk ($0.029)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -100% — the top line is shrinking
  • Overseas neutral (-1pts, S&P500 neutral, VIX 25)
Ask Scout AI about PAB
"What's driving PAB's score?" "How does PAB compare to peers?" "Key risks for PAB?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Notification of cessation of securities - PAB
NONE Change of Share Registry Details
NONE RLS-2201 Manufacturing and Regulatory Pathway Initiated
Announcement tone +3pts

Recent ASX Announcements

2026-03-18 Notification of cessation of securities - PAB
2026-03-13 Change of Share Registry Details
2026-03-10 RLS-2201 Manufacturing and Regulatory Pathway Initiated PRICE SENSITIVE
2026-02-26 Appendix 4D - Half Year Accounts - 31 December 2025 PRICE SENSITIVE
2026-02-15 CEO Commences Role

Key Metrics

$9.9M
Market Cap
950K
Avg Volume
0.8x
Vol Ratio
$0.03 — $0.05
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-260.6%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 63%
LLeader vs LaggardneutralRS: 1
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral
Related Tickers
RIV 48WOT 48MRE 46PCX 46VTM 45
Compare:PAB vs RIVPAB vs WOTPAB vs MRE
Scout Pro — Deeper Analysis for PAB
Try Pro free for 30 days
Share this analysis

Track PAB and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required